Meda's Astepro receives registration approval in Europe

NewsGuard 100/100 Score
Mar 21 2012

Astepro (STO:MEDAA) has received registration approval in Europe via the decentralized procedure. Astepro is a new nasal spray for the treatment of allergic rhinitis. National registration processes, including price and reimbursement, will now follow in each country. Launch is expected next year.

"We are pleased to announce the approval of Astepro in Europe. The product has been launched in the US with good success. With the addition of Dymista (currently in registration phase) Meda will have an extraordinary strong position in the allergy rhinitis area, both in the US and Europe", said Anders Lönner, CEO of Meda AB.

Source:

MEDA

Posted in: Medical Condition News | Pharmaceutical News

Tags: , , ,

Comments (0)

Suggested Reading

Study shows engineered antibodies significantly boost Omicron neutralization
Allergies linked to heightened risk of long COVID, new review suggests
Associations between mercury exposure and allergic diseases in children
Home dust chemicals predict asthma and allergies in children
Research confirms no association between SARS-CoV-2 and childhood asthma diagnoses
Interactomics-based analysis suggests that rhinitis and rhinitis with asthma are mechanistically different diseases
New insights: Gut microbiome alterations linked to rising allergic disease prevalence
Food allergies' broad impact on quality of life demands greater awareness

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
New, automated shake and fire platforms from Copley cut the burden of MDI and nasal drug product testing.